Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / AstraZeneca

Clinicaltrial registered12 Nov 2026

AstraZeneca

12 Nov 2026: Trial registered · A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
12 Nov 2026
Title
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
Conditions
Hypercholesterolemia
Phase
Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Countries
China, Hong Kong, Malaysia, South Korea, Thailand, Vietnam
Country
China
Reference
NCT07930507
Location
China, Hong Kong, Malaysia
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at AstraZeneca

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for AstraZeneca in our registers.

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.